Aroa Biosurgery (ASX:ARX) Cash, Cash Equivalents, Marketable Securities : A$27.73 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Aroa Biosurgery Cash, Cash Equivalents, Marketable Securities?

Aroa Biosurgery's quarterly cash, cash equivalents, marketable securities declined from Mar. 2023 (A$43.00 Mil) to Sep. 2023 (A$32.47 Mil) but then stayed the same from Sep. 2023 (A$32.47 Mil) to Mar. 2024 (A$27.73 Mil).

Aroa Biosurgery's annual cash, cash equivalents, marketable securities declined from Mar. 2022 (A$53.35 Mil) to Mar. 2023 (A$43.00 Mil) and declined from Mar. 2023 (A$43.00 Mil) to Mar. 2024 (A$27.73 Mil).

Aroa Biosurgery Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Aroa Biosurgery's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aroa Biosurgery Cash, Cash Equivalents, Marketable Securities Chart

Aroa Biosurgery Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

Cash, Cash Equivalents, Marketable Securities

42.42

33.94

53.35

43.00

27.73

Aroa Biosurgery Semi-Annual Data
	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial			53.35	44.11	43.00	32.47	27.73

Aroa Biosurgery Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Aroa Biosurgery (ASX:ARX) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Aroa Biosurgery Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Aroa Biosurgery's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Aroa Biosurgery (ASX:ARX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aroa Biosurgery Ltd (ASX:ARX) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022

Website

https://www.aroabio.com

Aroa Biosurgery Ltd is a soft tissue regeneration company which develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery.

Aroa Biosurgery (ASX:ARX) Headlines

No Headlines